Skip to Main Content

Press Releases

Press Release

Targeting a Novel Regulator of Mitochondrial Cell Death Delivers Anticancer Activity in Preclinical Studies

PHILADELPHIA — (Oct. 3, 2019) — A novel anticancer molecule created by researchers at The Wistar Institute showed therapeutic activity in preclinical models of various cancer types. This cell-permeable peptidomimetic was designed to disrupt a newly identified protein complex involving mitochondrial fission factor (MFF) and the voltage-dependent anion channel-1 (VDAC1), which regulates mitochondrial cell death. These results appeared online in the journal Cancer Research.

Press Release

Integral Molecular Announced as First Industry Partner in The Wistar Institute’s Biomedical Research Technician Apprenticeship

PHILADELPHIA – September 25, 2019 – The Wistar Institute, a global leader in cancer, immunology and infectious disease research, has selected Integral Molecular, Inc. as the first industry partner for its Biomedical Research Technician (BRT) Apprenticeship. This industry-academia relationship continues Integral Molecular’s dedication to community partnership, economic development, and job creation in the city of Philadelphia. 

Press Release

Wistar Receives More than $12 Million to Fund Innovative Clinical Research on the Impact of Opioid Use on Response to Therapy in People Living with HIV

PHILADELPHIA — (September 24, 2019) — The Wistar Institute was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to fund an international multidisciplinary clinical research consortium spearheaded by Wistar’s HIV Research Program. The consortium, including several partner institutions in the U.S.

Press Release

Identification of a Novel Regulator of Mitochondrial Cell Death Reveals a Promising Target for Cancer Therapy

PHILADELPHIA — (Sept. 18, 2019) — Researchers at The Wistar Institute have described the role of mitochondrial fission factor (MFF) in controlling survival of cancer cells, suggesting the protein could represent a promising therapeutic target. They also found that expression of MFF is regulated by Myc, a ubiquitous mediator of cell proliferation that contributes to development of many cancer types. These results were published online in the journal EBioMedicine.